Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

859
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
859
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

612
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
612
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

263
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
263
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

103
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
103
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

175
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
175
Liver Physiology01:30

Liver Physiology

872
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
872

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the fusion machinery of Peste des petits ruminants virus: design and in vitro characterization of an HRC-derived antiviral peptide.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Design and Characterization of an HRC-Derived Peptide Inhibitor of Canine Coronavirus Spike-Mediated Fusion.

Pathogens (Basel, Switzerland)·2026
Same author

Coffee Wastes: A Sustainable Source of Natural Compounds Suppressing Colorectal Cancer Cell Viability.

Oxidative medicine and cellular longevity·2026
Same author

Involvement of formyl peptide receptor 2 in canine coronavirus infection: in vitro and in Silico approaches.

Virology journal·2025
Same author

TLR2 c.374C>T variant linked to natural resistance against brucellosis in Italian Mediterranean river buffalo.

BMC veterinary research·2025
Same author

Tailoring Oxide/MAX Phase Nanocomposites via Low-Temperature Oxidation for Lithium-Ion Battery Anodes: Peeking Behind the Electrochemical Mechanism via In Situ Investigations.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Related Experiment Video

Updated: Aug 9, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

28.7K

Microbiota-Liver Diseases Interactions.

Rosanna Capparelli1, Paola Cuomo1, Antonio Gentile1

  • 1Department of Agriculture Sciences, University of Naples Federico II, 80055 Naples, Italy.

International Journal of Molecular Sciences
|February 25, 2023
PubMed
Summary
This summary is machine-generated.

This study explores CRISPR/Cas9 gene editing for liver diseases and colorectal cancer, highlighting the gut microbiota's role and the importance of studying pathobionts and multiple mutations in the gut-liver axis.

Keywords:
gut–microbiotaliver diseasespathobionts

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.7K

Related Experiment Videos

Last Updated: Aug 9, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

28.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.7K

Area of Science:

  • Microbiology and Genetics
  • Gastroenterology and Hepatology
  • Oncology

Background:

  • The gut microbiota is crucial for host metabolism, vitamin synthesis, fiber digestion, and pathogen protection.
  • Non-alcoholic fatty liver disease (NAFLD) affects over 25% of the global population, and colorectal cancer (CRC) is a leading cause of mortality.
  • Pathobionts and multiple mutations are critical factors in understanding gut health and disease pathogenesis.

Purpose of the Study:

  • To investigate the application of CRISPR/Cas9 gene editing technology in treating liver diseases.
  • To discuss the interplay between gut microbiota, non-alcoholic fatty liver disease (NAFLD), and colorectal cancer (CRC).
  • To emphasize the significance of studying pathobionts and multiple mutations within the gut-liver axis for cancer research.

Main Methods:

  • Review and discussion of CRISPR/Cas9 gene editing applications.
  • Analysis of existing literature on NAFLD and CRC.
  • Exploration of the role of pathobionts and multiple mutations in gut-liver axis diseases.

Main Results:

  • CRISPR/Cas9 technology shows promise for correcting genetic defects in liver diseases.
  • The gut microbiota composition is linked to the development and progression of NAFLD and CRC.
  • Pathobionts and multiple mutations represent complex etiological factors in gut-related cancers.

Conclusions:

  • CRISPR/Cas9 offers a potential therapeutic avenue for liver diseases.
  • Understanding the gut microbiota's role is vital for managing NAFLD and CRC.
  • Further research into pathobionts and multiple mutations is essential for advancing treatments for gut-liver axis cancers.